<DOC>
	<DOCNO>NCT02274740</DOCNO>
	<brief_summary>Primary Objective : To evaluate ability lixisenatide modulate postprandial hyperlipidemia particular , effect plasma change triglyceride . Secondary Objectives : The effect lixisenatide follow postprandial lipid : apolipoprotein ( APO ) B48 ; free fatty acid , lipoprotein distribution , cholesterol , low-density lipoprotein ( LDL ) oxidation . The effect lixisenatide chronic low-grade inflammation present non-insulin dependent diabetes mellitus ( NIDDM ) obesity . The effect lixisenatide microvascular dysfunction . To evaluate effect lixisenatide postprandial plasma glucose , insulin C-peptide glucagon .</brief_summary>
	<brief_title>Effect Lixisenatide Postprandial Lipid Profile Obese Type 2 Diabetic Patients</brief_title>
	<detailed_description>Maximum study duration approximately 2.5 month ( study treatment ) ± 2 day Day 0 ( baseline ) plus 10-week open-label , active-controlled treatment period ( Final/End-of-treatment Visit ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Male female patient , 1870 year age . Diagnosis Type 2 diabetes treat metformin obesity ( body mass index [ BMI ] &gt; 30 kg/m^2 ) follow abnormality : Abdominal obesity ( waist circumference &gt; 102 cm men &gt; 88 cm woman ) . According National Cholesterol Education ProgramAdult Treatment Panel ( NCEPATP ) III ( 2001 ) . Glycated hemoglobin A1c ( HbA1c ) ≥7 ≤8.5 % ( Sponsor approval provider might reasonably suggest stringent A1c goal [ 6.5 % ] select individual patient , achieve without significant hypoglycemia adverse effect treatment . Appropriate patient might include short duration diabetes , long life expectancy , significant cardiovascular disease ) . Hypertriglyceridemia ( fast triglyceride level 150 mg/dL 600 mg/dL , cholesterol &lt; 300 mg/dL . In order exclude patient might suffer primitive dyslipidemia ) . Low highdensity lipoprotein ( HDL ) cholesterol ( serum HDLcholesterol &lt; 40 mg/dL men &lt; 50 mg/dL woman ) . Written informed consent . Exclusion criterion : Smoking . Thyroid disease even appropriate hormonal replacement therapy thyroid suppressant ( Thyroid Stimulating Hormone [ TSH ] &gt; 5 mU/L clinical symptom hypothyroidism ) . Hepatic disease ( Aspartate Aminotransferase [ ASAT ] Alanine Aminotransferase [ ALAT ] &gt; 2 time upper limit normal ) . Renal disease ( serum creatinine &gt; 1.7 time upper limit normal ) . A history coronary heart disease , cerebrovascular disease , peripheral arterial disease 6 month enrollment . History malignancy . Use lipid lower therapy . Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg . Triglycerides &gt; 600 mg/dL . History chronic pancreatitis idiopathic acute pancreatitis . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>